论文部分内容阅读
目的观察替比夫定治疗HBeAg阳性慢性乙型肝炎(CHB)患者的疗效。方法将HBeAg阳性CHB患者100例随机分为治疗组和对照组,每组50例,治疗组给予替比夫定治疗,对照组给予恩替卡韦治疗。2组患者均每月检测肝功能、每隔3个月检测HBVM定量及血清HBV-DNA定量。结果 2组治疗3个月、6个月、12个月血生化指标差异均无统计学意义(P>0.05);2组治疗后3个月、6个月、12个月HBV-DNA转阴率对比差异均无统计学意义(P>0.05),2组治疗后3个月、6个月HBeAg血清转换率和阴转率比较差异无统计学意义(P>0.05),治疗12个月时2组HBeAg血清转换率和阴转率比较差异均有统计学意义(χ2=5.44,P=0.01963)。结论替比夫定治疗HBeAg阳性CHB患者可明显改善肝功能,提高治疗效果,值得临床推广应用。
Objective To observe the efficacy of telbivudine in the treatment of HBeAg-positive chronic hepatitis B (CHB) patients. Methods One hundred patients with HBeAg positive CHB were randomly divided into treatment group and control group, with 50 patients in each group. The treatment group was treated with telbivudine and the control group was treated with entecavir. Two groups of patients were tested for liver function every month, HBVM quantification and serum HBV-DNA quantification every 3 months. Results There was no significant difference in blood biochemical parameters between the two groups at 3 months, 6 months and 12 months (P> 0.05). After 2 months, 6 months and 12 months, the HBV-DNA negative (P> 0.05). There was no significant difference in HBeAg seroconversion rate and negative conversion rate between the two groups at 3 and 6 months after treatment (P> 0.05). After treatment for 12 months There were significant differences in HBeAg seroconversion rate and negative conversion rate between the two groups (χ2 = 5.44, P = 0.01963). Conclusion The treatment of HBeAg-positive CHB patients with telbivudine can significantly improve liver function and improve the therapeutic effect, which is worthy of clinical application.